Business
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief
About this update from Biocryst Pharmaceuticals, Inc.
[{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025. The board has appointed Charlie Gayer, currently the company’s chief commercial officer (CCO), as the company’s next president, effective August 1, 2025, and next chief executive officer, effective January 1, 2026. Mr. Stonehouse will continue to serve on the board of directors and Mr. Gayer will join the company’s board, effective January 1, 2026. Mr. Gayer has built and led the commercial organization responsible for the successful launch of ORLADEYO® (berotralstat), bringing the first oral prophylactic therapy to people with hereditary angioedema and driving exceptional revenue growth, with expected peak sales of $1 billion. He also has played a pivotal role in shaping the company’s recent business development strategy, including the planned sale of its European operations. “We want to thank Jon for building BioCryst into the commercial, profitable company it is today, with such a bright future,” said Nancy Hutson, chair of the board. “As part of our succession planning process, we have evaluated outstanding internal and external potential successors and Charlie stood out in that process, with an ability to build on the success he has achieved with ORLADEYO to further deliver on our mission to bring life-changing therapies to patients and create long-term value for our stakeholders.” “I am delighted to hand the leadership responsibility of the company to Charlie. He has a proven track record of delivering results and is largely responsible for one of the best commercial launches of a rare disease drug in recent history. Charlie is a purpose-driven leader who understands our company’s mission to serve patients living with rare diseases in extraordinary ways,” said Stonehouse. “I am thrilled the board chose Charlie, as he understands we have worked hard to build a special culture at BioCryst that we believe has a direct impact on the company’s performance in creating value. He is the perfect leader to take the company even further.” “I am grateful for Jon's leadership and the patients-first culture he has fostered over my 10 years at BioCryst. Under his guid...